The blockbuster diabetes and weight-loss drug semaglutide (Ozempic, Rybelsus, Wegovy) along with therapies for asthma, cancers, and various other conditions were among the 15 drugs the Biden administration selected for the next round of Medicare price negotiation.

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction Act. | The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction Act.

Semaglutide (Ozempic) is 1 of 15 medications that will be included in yearly price negotiations between Medicare and manufacturers.

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. CMS listed Ozempic, Rybelsus and Wegovy — all forms of

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.On Jan. 17, CMS announced it will commence negotiations with pharmaceutical companies to lower prices for Medicare Part D coverage for a wide range of drugs to treat multiple forms of cancer,

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before President-elect Donald Trump takes office.

Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health policy acts.

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.